Kornimate/medical-research-clean huggingface dataset:
to analyze the kinematic change of lower limb during jumping task with wearable device - 2-year program

Conditions: Landing Error Scoring System (LESS)

Summary: this study will be conducted in two years: in the first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability. in advance, the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer and basketball athletes. in the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue.

in taiwan, it was estimated that at least 1,000 cases of patients require anterior cruciate ligament (acl) reconstruction annually. despite the improving of surgical technique, there are only 65% patients who received the acl reconstruction return to their pre-injury level of sport. therefore, to prevent acl injuries in athletes is critical. the mechanism of acl injury is greatly associated with lower limb biomechanics. motional analysis is the golden standard for biomechanics. however, with the advancement in technology, the investigators could explore lower limb biomechanics conveniently by wearable device. but the validity and reliability need further confirmation. according to previous studies, the investigators could predict the possibility of acl injuries by the change of biomechanics, such as hip adduction, internal rotation and knee valgus. dynamic taping is a newly developing technique with better elasticity and extensibility. studies showed that dynamic taping improve the biomechanics of knee joint. hence, the investigators can adjust the faulty movement as soon as possible to prevent the occurrence of acl injuries. this study will be conducted in two years: in the first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability. in advance, the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer and basketball athletes. in the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue.

Eligibility criteria:
inclusion criteria: * 1st year: 16+ health volunteers * 2nd year: senior high school and college athlete exclusion criteria: * those who are unable to exercise due to acute joint, muscle or nerve injury in the lower extremities * lower extremity surgery within 1 year * head trauma within 6 months * those with vestibular injury within 6 months * allergic to dynamic tape * pregnant * visual coordination impairment

Keywords: dynamic taping landing error scoring system (less) acl injuries
papillomavirus in renal transplant patient

Conditions: Papillomavirus Infections

Summary: the main goal of project is to study the distribution of hpv genotypes in the anogenital area and peripheral humoral immune responses hpv (total and neutralizing ab) before and after renal transplantation. furthermore, the investigators wish (i) establish whether there is a correlation between hpv infection and hpv immune response before and after transplantation, and (ii) determine whether there is a link between hpv infection and immunosuppression.

kidney transplant patients, iatrogenic immunosuppression established, essential to limit the transplant. kidney transplant patients, iatrogenic immunosuppression established, essential to limit the transplant rejection, exposes patients to an increased risk of infections, including human papillomavirus (hpv). these patients thus constitute a population at risk of developing cancers associated with hpv. indeed, a recent meta-analysis indicated that the standardized incidence ratio for cancers associated with hpv increases dramatically in kidney transplant: sir of 2.13 (95% ci 1.37 to 3.30) for the cervical, ris 22.76 (95% ci 15.8 to 32.7) for the vulva and vagina, ris 15.8 (95% ci 5.79 to 34.40) for the penis, ris 4.85 (95% ci 1.36 to 17.3) and ris to the anus of 3.23 (95% ci 2.40 to 4.35) for the oral cavity and pharynx. in fact, transplant patients are subject to increased surveillance to detect the onset and / or progression of lesions (pre) cancerous, especially anogenital level. data on hpv infection in the genital area of kidney transplant patients are few and concern cohorts with a modest number of subjects. indeed, it is difficult to estimate the prevalence of infection and know precisely genotypes of hpv present in anogenital level. similarly, some studies report the presence of anti-hpv antibodies in transplant patients. the main goal of project is to study the distribution of hpv genotypes in the anogenital area and peripheral humoral immune responses hpv (total and neutralizing ab) before and after renal transplantation. furthermore, the investigators wish (i) establish whether there is a correlation between hpv infection and hpv immune response before and after transplantation, and (ii) determine whether there is a link between hpv infection and immunosuppression.

Eligibility criteria:
inclusion criteria: * patients aged over 18 years * patient waiting for first kidney transplant * patients receiving a social security scheme * postmenopausal women, surgically sterile or subjected to an effective method of contraception * patient who signed the written consent exclusion criteria: * patients who have been transplanted * pregnant women * emergency situation patients * patients unable to give consent personally * major protected patients * patients under judicial supervision

Keywords: kidney transplantation human papillomavirus
evaluating the optimal volume voided for passage of a backfill-assisted voiding trial following urogynecologic surgery

Conditions: Voiding Dysfunction

Summary: urinary retention can lead to bladder over-distention, ischemia, and long-term voiding dysfunction, and early identification of urinary retention can help prevent these adverse events

postoperative voiding trials (vt) can identify as well as prevent postoperative urinary retention. voiding trial protocols vary by provider and healthcare facilities/institutions as there is no consensus on how to prevent postoperative urinary retention optimally. identification of an optimal vt could not only help decrease adverse events associated with urinary retention but also decrease postoperative catheter-associated urinary tract infection (cauti) rates, unplanned hospital or clinic visits, and decrease patient discomfort while increasing patient satisfaction.

Eligibility criteria:
inclusion criteria: * nonpregnant women \>18yo undergoing pelvic organ prolapse or urinary incontinence surgery exclusion criteria: * patients undergoing fistula repair or sacral neuromodulation * voiding dysfunction preoperatively that requires intermittent self-catheterization * intraoperative bladder injury * pregnancy * preoperative uti (culture proven within 7 days prior to surgery)

Keywords: urinary tract infections overactive bladder pelvic organ prolapse surgery urinary incontinence surgery
effectiveness of castor oil in preventing formal induction of labour in a tertiary institution

Conditions: Castor Oil; Prolonged Pregnancy

Summary: this study demonstrated that castor oil was effective in reducing the need for formal induction of labour and the administration-delivery interval with minimal maternal side-effects, at an initial dose of 30ml and single repeat dose of 30ml.

background: pregnancy extending beyond 42 week is attended by maternal and perinatal complication including death. it is the commonest reason for induction of labour. various agents have been used to induce labour but it is not without maternal and fetal side effects. alternative agents such as castor oil have been widely used in clinical practice for induction of labour without any concrete evidence of effectiveness. objective: to evaluate the effectiveness of castor oil in the prevention of formal induction of labour amongst pregnant mothers at alex ekwueme federal university teaching hospital abakaliki as well as to evaluate the possible maternal and fetal/ neonatal effects. methods: this was a randomized controlled trial among pregnant women at alex ekwueme federal university teaching hospital abakaliki to verify the effectiveness of castor oil in the prevention of formal induction of labour at gestational ages between 41weeks and 0 days and 41 weeks and 2 days. one arm received 30ml of castor oil (group a) and the other arm received 30ml of water (group b). these doses were repeated once more after 24 hours if the patients failed to enter spontaneous labour. the data obtained was analyzed using ibm spss software (version 24, chicago ii, usa) and the intention to treat concept. a difference with a p value of ≤ 0.05 was taken to be of statistical significance.

Eligibility criteria:
inclusion criteria: 1. gestational age of 41weeks+0day to 41weeks+2days 2. pregnancies with cephalic presenting fetuses 3. pregnant women with singleton fetus 4. absence of contraindications to vaginal delivery 5. absence of uterine contraction 6. bishop score ≤ 5 7. ultrasound confirmed ga in early pregnancy exclusion criteria: 1. pregnant women in latent phase of labour 2. preterm or term premature rupture of membrane 3. antepartum haemorrhage 4. previous caesarean section and myomectomy 5. multiple gestation 6. medical disorders of pregnancy 7. unsure date

Keywords: castor oil induction of labour prolonged pregnancy
brief behavioral intervention for insomnia during chemotherapy

Conditions: Breast Cancer; Insomnia

Summary: primary objective(s): to evaluate the efficacy of the brief behavioral therapy for insomnia (bbt-i) in treating insomnia among breast cancer patients receiving chemotherapy. secondary objective(s): * to evaluate the efficacy of the bbt-i in treating cancer-related symptoms such as cancer-related fatigue and cognitive difficulties in breast cancer patients receiving chemotherapy. * to examine potential moderators and mediators of bbt-i intervention effects on insomnia, cognitive difficulties, and fatigue. in particular, we are interested in age, depression and anxiety and side effects (hot flashes) as potential moderators of the intervention effects as well as evaluating modifiable behavioral and physiological mechanisms as hypothesized mediators


Eligibility criteria:
inclusion criteria * female * diagnosis of breast cancer (stage i-iiia) * scheduled for planned cancer treatment (eg, chemotherapy or biologic agents), or treatment is continuing * has ≥ 6 weeks of cancer treatment (eg, chemotherapy or biologic agents) remaining * ≥ 21 years of age. * able to understand written and spoken english. * sleep disturbance of 8 or greater on the isi, and insomnia that began or got worse with diagnosis of cancer or treatment with chemotherapy (to exclude pre-existing, chronic insomnia). * karnofsky score ≥ 70 exclusion criteria * have an unstable self-reported medical or psychiatric illness (axis i - current or within the last 5 years). * be currently pregnant or nursing * history of substance abuse or meet criteria for current alcohol abuse or dependence * history (self-reported) of sleep apnea or restless leg syndrome (rls) * self-report or have a medical record of an unstable comorbid medical or psychiatric condition that would make it unsafe or impossible to adhere to the study protocol * unable or unwilling to discontinue anxiolytics within 4 hours of education sessions * irregular heartbeat or arrhythmia (self-reported or in the medical record)
s0309, repository: blood/bone marrow from pts. with myeloma, wm, amyloidosis, or mgus.

Conditions: Multiple Myeloma; Smoldering Myeloma; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Amyloidosis

Summary: rationale: collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer. purpose: the purpose of this study is to collect and store blood and bone marrow samples from patients with multiple myeloma, smoldering myeloma, waldenstrom's macroglobulinemia, amyloidosis, and monoclonal gammopathy of undetermined significance to be tested in the laboratory.

objectives: * maintain and expand tissue repositories of myeloma specimens from uniformly treated southwest oncology group (swog) patients with multiple myeloma, smoldering myeloma, waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance. * utilize scientific information generated from intergroup and collaborative studies to assist the swog myeloma committee in the development of new and more effective treatment regimens for these patients. outline: patients receive treatment as directed by the treatment protocols on which they are registered. specimens of blood and/or marrow are submitted to the myeloma repository. the status of the patient (e.g., pre-study, post-remission, or relapse) will be recorded prior to specimen collection. projected accrual: not specified

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following: * multiple myeloma * smoldering myeloma * waldenstrom's macroglobulinemia * amyloidosis * monoclonal gammopathy of undetermined significance * must be currently registered on a southwest oncology group-coordinated treatment study (swog or intergroup) * must have pretreatment specimens to submit to this study * no cytogenetic samples patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: multiple myeloma waldenström macroglobulinemia monoclonal gammopathy of undetermined significance primary systemic amyloidosis
study of isis 678354 (akcea-apociii-lrx) in participants with hypertriglyceridemia and established cardiovascular disease (cvd)

Conditions: Hypertriglyceridemia; Cardiovascular Diseases

Summary: this was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of isis 678354 and to assess the efficacy of different doses and dosing regimens of isis 678354 for reduction of serum triglyceride (tg) levels in participants with hypertriglyceridemia and established cvd or at a high risk for cvd.


Eligibility criteria:
key inclusion criteria: * clinical diagnosis of cvd (defined as documented coronary artery disease, stroke, or peripheral artery disease). * fasting serum triglycerides (tg) greater than or equal to (≥) 200 milligrams per deciliter (mg/dl) (≥ 2.3 millimoles per liter (mmol/l)) and less than or equal to (≤) 500 mg/dl (≥ 5.7 mmol/l) at screening. * fasting tg ≥ 200 mg/dl and ≤ 500 mg/dl at qualification visit. * must be on standard-of-care preventative therapy for known cvd risk factors. key exclusion criteria: * within 6 months of screening: acute coronary syndrome, major cardiac surgery, or stroke/transient ischemic attack (tia). * within 3 months of screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis. * heart failure new york heart association (nyha) class iv. * type 1 diabetes mellitus. * type 2 diabetes mellitus with any of the following: * newly diagnosed within 12 weeks of screening. * glycated hemoglobin (hba1c) ≥ 9.0% at screening. * recent change in anti-diabetic pharmacotherapy (change in dosage or addition of new medication within 12 weeks of screening \[with the exception of ± 10 units of insulin\]. * body mass index (bmi) greater than (\>) 40 kilograms per square meter (kg/m\^2).

Keywords: akcea-apociii-lrx ionis-apociii-lrx dyslipidemia metabolic disease hyperlipidemia cardiac disease lipid metabolism disorders triglycerides high vascular diseases
periprostatic nerve block vs. intravenous ibuprofen for pain management during transrectal prostate biopsy

Conditions: Pain, Acute

Summary: this study aimed to compare the efficacy of intravenous ibuprofen with peri-prostatic nerve block in pain control during prostate biopsy and to investigate factors influencing pain scores.

this study aimed to compare the efficacy of intravenous (iv) ibuprofen with periprostatic nerve block (ppnb) in controlling pain during prostate biopsy, a common procedure used to diagnose prostate cancer. the study also aimed to investigate factors influencing pain perception during the procedure, such as prostate-specific antigen (psa) levels, prostate volume, and comorbidities.

Eligibility criteria:
inclusion criteria: male gender. scheduled for a prostate biopsy. prostate-specific antigen (psa) levels \> 4 ng/ml. exclusion criteria: renal failure. liver failure. neurological disorders (e.g., dementia, alzheimer's disease, epilepsy, paraplegia). rectal disorders. previous negative prostate biopsy. chronic anticoagulant therapy or bleeding diathesis. severe comorbidities. psychiatric conditions interfering with consent or compliance.

Keywords: prostate biopsy ıv ibuprofen periprostatic nerve block visual analog scale
propofol and fentanyl versus midazolam and fentanyl for endoscopy sedation in cirrhotic patients

Conditions: Cirrhosis

Summary: the purpose of this study is to compare propofol associated with fentanyl versus midazolam plus fentanyl for sedation during diagnosis or therapeutic upper gastrointestinal endoscopy (uge) in cirrhotic patients.

uge is often performed in cirrhotic patients for the diagnosis and treatment of portal hypertension complications. current data suggests that propofol sedation may have advantages over benzodiazepines. however, there are few reports comparing propofol versus midazolam in patients with liver cirrhosis. the study's objective is to compare propofol associated with fentanyl versus midazolam plus fentanyl for sedation during diagnosis or therapeutic uge in cirrhotic patients. a prospective randomized study will include cirrhotic patients (child a, b or c and asa 2 or 3), referred for diagnostic or therapeutic uge, randomized for group i: propofol (0,5 mg/kg up to 400 mg) and fentanyl (0,05 mg); or group ii: midazolam (0,1 mg/kg) and fentanyl. sedation was performed by an exclusively dedicated gastroenterologist. efficacy (completion of procedures), complications (hypoxemia, hypotension, arrhythmias) and recovery time (elapsed from the end of the procedure and discharge) will be studied.

Eligibility criteria:
inclusion criteria: * liver cirrhosis, any etiology * asa ii or iii * child a, b or c * age between 18 years and 75 years * patients that agree in participate of study and signed the contentment term exclusion criteria: * schistosomiasis * recuse * hepatocellular carcinoma * contraindications to drugs * asa iv or v * hepatic encephalopathy, neurologic diseases * opioids, narcotics, mao inhibitors or benzodiazepines use * alcohol abuse

Keywords: propofol midazolam cirrhosis gastrointestinal endoscopy complications sedation
a combined biofeedback-virtual reality system for reduction of fear of hypoglycemia

Conditions: Hypoglycemia; Type One Diabetes

Summary: uncontrolled diabetes is associated with increased risk for micro-vascular complication. hypoglycemia is one of the major barriers in achieving good glucose control. hypoglycemia is associated with a range of unpleasant symptoms including palpitations, tremor, hunger, sweating, confusion, difficulties in thinking as well as other idiosyncratic symptoms. fear of hypoglycemia (foh) refers to phobic avoidance reactions associated with hypoglycemia foh may increase behavioral attempts to avoid hypoglycemia including decreased consumption of insulin and/or increased consumption of carbohydrates, resulting in poor glycemic control and an increased risk of diabetic complication. in this study, the investigators present a novel system, which simultaneously employs biofeedback and virtual reality in order to cope with fear of hypoglycemia.


Eligibility criteria:
inclusion criteria: * type 1 diabetic patient, male and females above the age of 18. * patients with significant fear of hypoglycemia as indicated in the hfs-w (equals or greater than 3 on at least one of the item on the hfs-w ). exclusion criteria: patient with severe hypoglycemia event in the last 6 months will be excluded. patient with mental illness will be excluded
prevention of hypergranulation tissue after gastrostomy tube placement

Conditions: Soft Tissue Inflammation

Summary: the primary objective of this study is to compare the incidence of postoperative hypergranulation tissue formation after gastrostomy tube placement among children randomized to one of three treatments, in addition to measuring tube dislodgements and rates of resource utilization for complications.

hypergranulation tissue is one of the major immediate complications of gastronomy tube placement. this study aims to determine if using a foam dressing upon placement will prevent its formation, as it has been demonstrated as an effective treatment in healing hypergranulation tissue formation post-operatively. study participants will be randomized into one of three treatments after gastronomy tube placement (1) standard care, (2) plain foam treatment or (3) silver foam dressing. these treatments will be applied for 30 days post-operatively in addition to standard care of cleaning the gastronomy site daily with soap and water, if assigned to foam intervention. all study materials are free for duration of 30 day intervention and participation will not interfere with routine post-operative care of gastronomy tube site. the total duration of trial will be 6 months and will not require additional study visits outside of routine care. the rate of g-tube dislodgements and associated outcomes will also be measured during the trial.

Eligibility criteria:
inclusion criteria: * children between 1 month and 17 years of age who undergo gastrostomy tube placement by a member of the pediatric surgery faculty at children's memorial hospital will be eligible for inclusion in this study. exclusion criteria: * children undergoing gastrostomy tube placement by gastroenterology or interventional radiology at children's memorial hospital. * mother or caregiver of the patient is currently pregnant, breastfeeding and/or planning on getting pregnant within the next 60 days (silver hd has not been studied in pregnant or breastfeeding women)

Keywords: hypergranulation tissue gastrostomy tube hydrocolloid dressing silver hydrocolloid dressing gastrostomy tube dislodgement wound infection peristomal skin breakdown